Nevro Gestione

Gestione criteri di controllo 1/4

Nevro Il CEO è Kevin Thornal, nominato in Apr2023, e ha un mandato di 1.58 anni. la retribuzione annua totale è $ 11.45M, composta da 4.5% di stipendio e 95.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.084% delle azioni della società, per un valore di € 136.49K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 5.3 anni.

Informazioni chiave

Kevin Thornal

Amministratore delegato

US$11.5m

Compenso totale

Percentuale dello stipendio del CEO	4.5%
Mandato del CEO	1.6yrs
Proprietà del CEO	0.08%
Durata media del management	1.7yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kevin Thornal rispetto agli utili di Nevro?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$69m
Jun 30 2024	n/a	n/a	-US$77m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$11m	US$516k	-US$92m

Compensazione vs Mercato: La retribuzione totale di Kevin ($USD 11.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 793.15K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Kevin con le performance aziendali.

AMMINISTRATORE DELEGATO

Kevin Thornal (50 yo)

1.6yrs

Mandato

US$11,453,548

Compensazione

Mr. Kevin R. Thornal serves as President & Chief Executive Officer at Nevro Corp. since April 24, 2023 and serves as its Director since May 2023. He joined Nevro Corp. on April 24, 2023. He serves as Acti...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Thornal	President	1.6yrs	US$11.45m	0.084% € 136.5k
Roderick MacLeod	Senior VP & CFO	4.4yrs	US$2.58m	0.066% € 107.5k
Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	6.9yrs	US$2.55m	0.13% € 212.6k
Greg Siller	Senior VP & Chief Commercial Officer	1.4yrs	US$3.56m	0.058% € 94.6k
Christofer Christoforou	Senior VP & COO	less than a year	US$2.87m	0.077% € 125.7k
Angeline McCabe	Vice President of Investor Relations & Corporate Communications	less than a year	Nessun dato	Nessun dato
Shana Ross	Senior VP & Chief Human Resources Officer	1.8yrs	Nessun dato	Nessun dato
David Caraway	Senior VP & Chief Medical Officer	10.6yrs	Nessun dato	Nessun dato
Peter Socarras	VP, General Counsel & Corporate Secretary	no data	Nessun dato	Nessun dato

1.7yrs

Durata media

50.5yo

Età media

Gestione esperta: Il team dirigenziale di 1N7 non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Thornal	President	1.5yrs	US$11.45m	0.084% € 136.5k
Susan Siegel	Independent Director	3.9yrs	US$242.99k	0.034% € 55.5k
Shawn McCormick	Independent Director	10.2yrs	US$246.99k	0.072% € 116.6k
Elizabeth Weatherman	Independent Director	5.7yrs	US$259.24k	0.16% € 267.7k
D. Grossman	Non-Executive Chairman of the Board	5.7yrs	US$1.48m	0.52% € 849.3k
Michael DeMane	Independent Lead Director	13.7yrs	US$284.99k	1.27% € 2.1m
Kevin O'Boyle	Independent Director	5.7yrs	US$259.99k	0.065% € 105.1k
Kirt Karros	Independent Director	less than a year	Nessun dato	Nessun dato
Karen Prange	Independent Director	4.9yrs	US$252.99k	0.039% € 64.1k
Sridhar Kosaraju	Independent Director	3.1yrs	US$242.99k	0.062% € 100.6k

5.3yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1N7 sono considerati esperti (durata media dell'incarico 5.3 anni).

Nevro Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nevro Corp., Annual General Meeting, May 23, 2024

Independent Director recently bought €160k worth of stock

Nevro Corp. Announces Executive Changes

Nevro Corp. Announces Executive Changes

General Counsel recently bought €95k worth of stock

Nevro Corp., Annual General Meeting, May 26, 2022

Recent updates

Nevro Corp. Announces the Publication of New Data in Medical Devices

Third quarter 2024 earnings released: US$0.41 loss per share (vs US$0.65 loss in 3Q 2023)

Nevro Corp. Reaffirms Earnings Guidance for the Year 2024

Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings released: US$0.53 loss per share (vs US$0.69 loss in 2Q 2023)

Nevro Revises Earnings Guidance for the Full Year 2024

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.98 loss in 1Q 2023)

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$0.085 profit in FY 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Nevro Corp. Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released: US$0.65 loss per share (vs US$2.30 profit in 3Q 2022)

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.71 loss in 2Q 2022)

Independent Director recently bought €160k worth of stock

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.98 loss in 1Q 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings released: EPS: US$0.085 (vs US$3.77 loss in FY 2021)

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: EPS: US$2.30 (vs US$1.44 loss in 3Q 2021)

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Nevro Corp. Announces Executive Changes

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2021)

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

General Counsel recently bought €95k worth of stock

First quarter 2022 earnings released: US$0.98 loss per share (vs US$0.85 loss in 1Q 2021)

Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022

Nevro Corp., Annual General Meeting, May 26, 2022

Nevro Corp. to Report Q1, 2022 Results on May 04, 2022

Chairman of the Board recently bought €187k worth of stock

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Nevro Announces Publication of Twelve Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine

Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)

Nevro Corp. Announces Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy

Nevro Corp. Announces Unitedhealthcare Coverage for High-Frequency 10 KHZ Therapy for the Treatment of Painful Diabetic Neuropathy

Independent Director recently bought €178k worth of stock

Nevro Corp. Announces Settlement of IP Litigation with Nalu Medical

Nevro Corp. Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy

General Counsel recently bought €176k worth of stock

Third quarter 2021 earnings released: US$1.44 loss per share (vs US$0.29 loss in 3Q 2020)

High number of new directors

Nevro Corp. Withdraws Full Year 2021 Guidance

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$1.21 loss in 2Q 2020)

Nevro Corp. Provides Preliminary, Unaudited Revenue Guidance for the Second Quarter of 2021

Nevro Corp. SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions